No photo of Kari Laiho

Kari Laiho

If you made any changes in Pure these will be visible here soon.

Publications 2017 2017


Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Vaananen, T., Vuolteenaho, K., Kautiainen, H., Nieminen, R., Mottonen, T., Hannonen, P., Korpela, M., Kauppi, M. J., Laiho, K., Kaipiainen-Seppanen, O., Luosujarvi, R., Uusitalo, T., Uutela, T., Leirisalo-Repo, M., Moilanen, E. & NEO-RACo Study Grp, 25 Aug 2017, In : PLoS One. 12, 8, 15 p., 0183294.

Research output: Contribution to journalArticleScientificpeer-review

Open Access

Three out of four disease-modifying anti-rheumatic drug-naive rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12months: results from the FIN-ERA cohort

Rannio, T., Asikainen, J., Hannonen, P., Yli-Kerttula, T., Ekman, P., Pirilä, L., Kuusalo, L., Mali, M., Puurtinen-Vilkki, M., Kortelainen, S., Paltta, J., Taimen, K., Kauppi, M., Laiho, K., Nyrhinen, S., Makinen, H., Isomaki, P., Uotila, T., Aaltonen, K., Kautiainen, H. & 1 othersSokka, T., 2017, In : Scandinavian Journal of Rheumatology. 46, 6, p. 425-431 7 p.

Research output: Contribution to journalArticleScientificpeer-review